Cetuximab in the management of colorectal cancer

Biologics: Targets and Therapy

Volumn 1, Issue 2, 2007, Pages 77-91

  Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cetuximab; Colorectal cancer; Epidermal growth factor receptor

Indexed keywords

EID: 77958163665     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Amgen Inc. 2007. Amgen discontinues Vectibix(TM) treatment in PACCE trial evaluating Vectibix(TM) as part of triple combination regimen: preliminary pre-planned interim analysis shows negative effect on progression-free survival [online; March 22, 2007 press release]. Accessed June 12, 2007. URL: http://www.amgen.com.
2. Andre T, Tabernero J, Van Cutsem E, et al. 2007. Phase II study with cetuximab plus FOLFOX-4 in first-line setting for epidermal growth factor (EGFR)-expressing metastatic colorectal cancer (mCRC): final results [abstract]. J Clin Oncol, 25(Suppl):334. Abstract 334.
3. Bokemeyer C, Bondarenko I, Makhson A, et al. 2007. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. [abstract]. J Clin Oncol, 25(Suppl):4035. Abstract 4035.
4. Bokemeyer C. 2005. OPUS: oxaliplatin and cetuximab in first-line treatment of mCRC [protocol]. Accessed on March 27, 2007. URL: www.medizin.uni-tuebingen.de/extweb/labor/ZGO/Pdf/Kolon_4.pdf.
5. Bonner JA, Harari PM, Giralt J, et al. 2006. Radiotherapy plus Erbitux for squamous-cell carcinoma of the head and neck. New Engl J Med, 354:567-78.
6. Cartron G, Watier H, Golay J, et al. 2004. From the bench to the bedside: ways to improve rituximab efficacy. Blood, 104:2635-42.
7. Chen HX, Mooney M, Boron M, et al. 2006. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol, 24:3354-60.
8. Chung KY, Fusco A, Park V, et al. 2007. Evaluation of routine antihistamine premedication after the first 2 doses of cetuximab [abstract]. Proc Am Soc Clin Oncol GI, Abstract 357.
9. Chung KY, Shia J, Kemeny NE, et al. 2005. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol, 23:1803-10.
10. Ciardiello F, Bianco R, Damiano V, et al. 1999. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res, 5:909-16.
11. Cunningham D, Humblet Y, Siena S. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351:337-45.
12. Cunningham D, Pyrhönen S, James RD, et al. 1998. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352:1413-8.
13. de Gramont A, Figer A, Seymour M, et al. 2000. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18:2938-47.
14. De Roock W, De Schutter J, De Hertogh G, et al. 2007. KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab [abstract]. J Clin Oncol, 25(18S):4132. Abstract 4132.
15. Di Fiore F, Blanchard F, Charbonnier F, et al. 2007. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer, 96:1166-9.
16. Dittmann K, Mayer C, Fehrenbacher B, et al. 2005. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem, 280:31182-9.
17. Douillard JY, Cunningham D, Roth AD, et al. 2000. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355:1041-7.
18. Engstrom PF, Arnoletti JP, Benson AB, et al. Colon cancer. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. V.1.2007.
19. ® (Cetuximab) Package Insert. 2006. ImClone Systems Incor- porated, New York, NY 10014 and Bristol-Myers Squibb Company, Princeton, NJ 08543; August 2006.
20. Fakih MG, Wilding G, Lombardo J. 2006. Cetuximab-induced hypomag- nesemia in patients with colorectal cancer. Clin Colorectal Cancer, 6:152-6.
21. Folprecht G, Lutz MP, Schöffski P, et al. 2006. Cetuximab and irinote- can/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal cancer. Ann Oncol, 17:450-6.
22. Giantonio BJ, Catalano PJ, Meropol NJ, et al. 2007. Bevacizumab in com- bination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol, 25:1539-44.
23. Goldsby RA, Kindt TJ, Osborne BA, et al. Immunology. 5th Edition. New York, NY: WH Freedman and Company; 2003.
24. Grothey A, Sargent D. 2005. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line [letter]. J Clin Oncol, 23:9441-2.
25. Grothey A, Sargent D, Goldberg RM, et al. 2004. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 22:1209-14.
26. Grothey A, Sugrue M, Hedrick E, et al. 2007. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE) [abstract]. J Clin Oncol, 25(Suppl):4036. Abstract 4036.
27. Harding J, Burtness B. 2005. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today, 41:107-27.
28. Hofheinz R-D, Horisberger K, Woernle C, et al. 2006. Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys, 66:1384-90.
29. Hu JC, Sadeghi P, Pinter-Brown LC, et al. 2007. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol, 56:317-26.
30. Huang SM, Bock JM, Harari PM. 1999. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosen-sitivity in squamous cell carcinomas of the head and neck. Cancer Res, 59:1935-40.
31. Hurwitz H, Fehrenbacher L, Novotny W, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350:2335-42.
32. Iannello A, Ahmad A. 2005. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anticancer monoclonal antibodies. Cancer Met Rev, 24:487-99.
33. Iannello S, Belfiore F. 2001. Hypomagnesemia: a review of pathophysiologi- cal, clinical, and therapeutic aspects. Panminerva Med, 43:177-209.
34. Jonker DJ, Karapetis CS, Moore M, et al. 2007. Randomized phase III trial of cetuximab monotherapy plus best supportive care [BSC] versus BSC Alone in patients with pretreated metastatic epidermal growth factor receptor [EGFR]-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG) [abstract]. Proc Am Assoc Cancer Res, Abstract LB-1.
35. Kawaguchi Y, Kono K, Mimura K, et al. 2007. Cetuximab induce antibody- dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer, 120:781-7.
36. Kelly K, Herbst RS, Crowley JJ, et al. 2006. Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): a randomized phase II selectional trial SWOG 0342 [abstract]. J Clin Oncol, 24(Suppl):7015. Abstract 7015.
37. ®) [abstract]. Proc Am Assoc Cancer Res, Abstract 5670.
38. INK4B and induces G1 arrest in oral squamous carcinoma cell lines. Oncology, 63:92-8.
39. Kurai J, Chikumi H, Hashimoto K, et al. 2007. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res, 13:1552-61.
40. Lang I, Zaluski J, Changchien CR, et al. 2006. Cetuximab with irinotecan in first-line treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): preliminary safety results (CRYSTAL) [abstract]. J Clin Oncol, 24(Suppl):3555. Abstract 3555.
41. Lenz H-J. 2006. Anti-EGFR mechanism of action: antitumor effect and underlying cause and adverse events. Oncology, 20(5 Suppl):5-13.
42. Lenz H-J, Van Cutsem E, Khambata-Ford S, et al. 2006. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol, 24:4914-21.
43. Lenz H, Zhang W, Yang D, et al. 2007. Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan- refractory colorectal cancer [abstract]. Proc Am Soc Clin Oncol GI, Abstract 401.
44. Lievre A, Bachet J-B, Le Corre D, et al. 2006. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 66:3992-5.
45. Machiels J-P, Sempoux C, Scalliet P, et al. 2007. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol, 18:738-44.
46. Nicholson RI, Gee JM, Harper ME. 2001. EGFR and cancer prognosis. Eur J Cancer, 37(Suppl 4):S9-15.
47. Overholser JP, Prewett MC, Hooper AT, et al. 2000. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer, 89:74-82.
48. Perez-Soler R, Saltz L. 2005. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol, 23:5235-46.
49. Pfeiffer P, Bjerregaard JK, Qvortrup C. 2007. Bi-weekly cetuximab (Cet) and irinotecan (Iri) as third-line therapy in patients with advanced colorectal cancer (ACRC) [abstract]. Proc Am Soc Clin Oncol GI, Abstract 305.
50. Prewett MC, Hooper AT, Bassi R, et al. 2002. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res, 8:994-1003.
51. Punt C. JA for the Dutch Colorectal Cancer Group. 2005. Cetuximab, capecitabine, oxaliplatin and bevacizumab in advanced colorectal cancer [protocol identifier: NCT00208546; study ID Number: CAIRO2]. Accessed March 28, 2007. URL: http://www.clinicaltrials.gov.
52. Rosell R, Daniel C, Ramlau R, et al. 2004. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC) [abstract]. J Clin Oncol, 22(Suppl):7012. Abstract 7012.
53. Rougier P, Van Cutsem E, Bajetta E, et al. 1998. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 352:1407-12.
54. Saltz LB, Cox JV, Blanke C, et al. 2000. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med, 343:905-14.
55. Saltz LB, Lenz H, Kindler H, et al. 2005. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/ bevacizumab (CB) in irinotecan-refractory colorectal cancer [abstract]. Proc Am Soc Clin Oncol GI, Abstract 169b.
56. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. 2004. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 22:1201-8.
57. Saltz L, Rubin M, Hochester H, et al. 2001. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract]. Proc Am Soc Clin Oncol, 20:Abstract 7.
58. Schrag D, Chung KY, Flombaum C, et al. 2005. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst, 97:1221-4.
59. Sobrero AF, Fehrenbacher L, Rivera F, et al. 2007. Randomized phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin- based therapy: the EPIC trial. 2007 [abstract]. Proc Am Assoc Cancer Res, Abstract LB-2.
60. Souglakos J, Kalykaki A, Vamvakas L, et al. 2007. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol, 18:305-10.
61. Spano J-P, Lagorce C, Atlan D, et al. 2005. Impact of EGFR expression on colorectal cancer patients prognosis and survival. Ann Oncol, 16:102-8.
62. Tabernero J, Cervantes A, Martinelli E, et al. 2006. Optimal dose of cetuximab (C) given every 2 weeks (q2w): a phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol, 24(18S):3085. Abstract 3085.
63. Tournigand C, André T, Achille E, et al. 2004. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 22:229-37.
64. Vallböhmer D, Lenz H-J. 2005a. Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer, 5(Suppl 1):S19-27.
65. Vallböhmer D, Zhang W, Gordon M, et al. 2005b. Molecular determinants of cetuximab efficacy. J Clin Oncol, 23:3536-44.
66. Van Cutsem E, Nowacki M, Lang I, et al. 2007. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial [abstract]. J Clin Oncol, 25(18S):4000. Abstract 4000.
67. Van Cutsem E, Humblet Y, Gelderblom J, et al. 2007. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic and efficacy data of a randomized study [abstract]. Proc Am Soc Clin Oncol GI, Abstract 237.
68. van Sorge NM, van der Pol WL, van de Winkel JGJ. 2003. FcγR polymor- phisms: implications for function, disease susceptibility and immuno-therapy. Tissue Antigens, 61:189-202.
69. Venook AP, Blanke CD, Goldberg RM, et al. 2006a. Assessing the combina- tion of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer. Commun Oncol, 3:593-8.
70. Venook A, Niedzwiecki D, Hollis D, et al. 2006b. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (mCRC): CALGB 80203 preliminary results [abstract]. J Clin Oncol, 2006:3509.
71. Wainberg Z, Hecht JR. 2006. Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin Biol Ther, 6:1229-35.
72. Wells A. 1999. EGF receptor. Int J Biochem Cell Biol, 31:637-43.
73. Weng W-K, Levy R. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol, 21:3940-7.
74. Whang R, Hampton EM, Whang DD. 1994. Magnesium homeostasis and clinical disorders of magnesium deficiency. Ann Pharmacother, 28:220-6.
75. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signaling network. Nature Rev Mol Cell Biol, 2:127-137.
76. Zhang W, Gordon M, Schultheis A, et al. 2007. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuzimab. J Clin Oncol, 25:3712-18.